Enovis Corporation
NYSE:ENOVMedical - Devices
+$0.73 today
- Market cap
- $1.56B
- Beta
- 1.49
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$20.02
Volume 0.88M
Average 0.99M
ENOV Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Enovis CorporationNYSE: ENOV
Gross Profit · Q1 FY2026 · quarter ended Apr 2026
Gross profit dips below year-ago levels
Q1 FY2026 gross profit of $323.58M fell 2.6% year over year, behind the +6.5% change in trailing-twelve-month gross profit. Sequentially, it fell 7.4% from the prior quarter. Over 3 fiscal years it compounded at +15.7% a year.
Context
- Gross profit amounted to 59.8% of revenue in FY2025, up 3.8 pp from a year earlier.
- Gross profit increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.6% toward the trailing-twelve-month pace of +6.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 1.35B USD
- Year-over-year change
- +13.9%
- 4-year CAGR
- +14.7%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.35B | +13.9% |
| FY2024 | 2024-12-31 | 1.18B | +19.2% |
| FY2023 | 2023-12-31 | 990.78M | +14.0% |
| FY2022 | 2022-12-31 | 869.38M | +11.8% |
| FY2021 | 2021-12-31 | 777.68M | — |
Gross Profit vs competitors
How ENOV compares with its peers on the latest reported figures
- ENOV's LTM Apr 2026 gross profit of $1.29B is the 6th highest of the 16 companies compared; the peer median is $512.06M.
- Its year-over-year change of +6.5% is the 9th highest of 16, against a peer median of +7.0%.
- Gross profit amounts to 56.8% of revenue for ENOV, versus a peer median of 35.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.64B | +26.9% | +14.7% | 34.6% | |
| LTM Jun 2026 | $1.6B | +10.5% | -1.2% | 44.7% | |
| LTM Jul 2026 | $1.36B | -7.2% | -4.7% | 38.0% | |
| LTM Jul 2026 | $1.35B | +4.6% | +5.1% | 34.6% | |
| LTM Jun 2026 | $1.31B | +18.0% | +11.3% | 48.8% | |
| LTM Apr 2026 | $1.29B | +6.5% | +15.7% | 56.8% | |
| LTM Sep 2026 | $801.1M | +7.0% | +3.0% | 35.4% | |
| LTM Jun 2026 | $523.5M | +13.2% | +4.8% | 42.8% | |
| LTM Jul 2026 | $512.06M | +11.2% | +6.9% | 44.4% | |
| LTM Feb 2026 | $303.73M | +0.4% | +4.9% | 48.6% | |
| LTM Jul 2026 | $291.3M | +20.4% | -3.1% | 32.7% | |
| LTM Jun 2026 | $214.56M | +3.0% | +14.5% | 30.6% | |
| LTM Mar 2026 | $89.7M | +1.1% | -2.1% | 24.1% | |
| LTM Mar 2026 | $57.75M | +9.2% | +31.5% | 23.5% | |
| LTM Mar 2026 | $54.26M | -11.4% | -11.0% | 55.3% | |
| LTM Apr 2026 | $35.75M | -1.1% | -20.0% | 19.7% | |
| Peer median (excluding ENOV) | $512.06M | +7.0% | +4.8% | 35.4% | |
Competitors are the stored peer set for ENOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B |
| Cost of Revenue | 648.51M | 693.72M | 716.42M | 926.87M | 902.79M |
| Gross Profit | 777.68M | 869.38M | 990.78M | 1.18B | 1.35B |
| Gross Margin | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| Research & Development | 49.09M | 60.83M | 75.33M | 91.3M | 120.33M |
| Selling, General & Admin | 665.78M | 772.91M | 830.31M | 939.36M | 1.07B |
| Operating Expenses | 840.47M | 940.56M | 1.06B | 1.96B | 1.36B |
| Depreciation & Amortization | 262.92M | 219.71M | 217.11M | 284.8M | 294.38M |
| EBITDA | 170.25M | 241.69M | 169.73M | (481.03M) | (830.22M) |
| EBITDA Margin | 11.9% | 15.5% | 9.9% | -22.8% | -36.9% |
| Operating Income | (62.8M) | (71.18M) | (65.71M) | (775.72M) | (18.87M) |
| Operating Margin | -4.4% | -4.6% | -3.8% | -36.8% | -0.8% |
| Interest Income | 0 | 200K | 0 | 0 | 0 |
| Interest Expense | 29.11M | 24.95M | 19.75M | 57.1M | 34.82M |
| Other Income / Expenses | (58.98M) | 69.11M | (1.42M) | (47.21M) | (1.14B) |
| Income Before Tax | (121.78M) | (2.07M) | (67.13M) | (822.92M) | (1.16B) |
| Pre-Tax Margin | -8.5% | -0.1% | -3.9% | -39.0% | -51.6% |
| Income Tax Expense | (19.53M) | 36.12M | (13.29M) | 4.49M | 22.29M |
| Net Income | 71.66M | (13.29M) | (33.26M) | (825.49M) | (1.18B) |
| Net Margin | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
| EPS (Basic) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| EPS (Diluted) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| Weighted Avg Shares | 51.14M | 54.07M | 54.53M | 55.28M | 56.79M |
| Weighted Avg Shares (Diluted) | 51.14M | 54.07M | 54.49M | 55.28M | 56.79M |
Enovis Corporation
NYSE:ENOV
Intrinsic Alpha fair value
Locked
Current Price
$27.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.